Bessemer Group’s vTv Therapeutics VTVT Stock Holding History

Bessemer Group’s Portfolio VTVT Stock Details VTVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4K	Hold	112	–	–	﹤0.01%	2330
2026 Q1	$4K	Hold	112	–	–	﹤0.01%	2288
2025 Q4	$4K	Buy	+112	New	+$3.12K	﹤0.01%	2308

Other funds holding VTVT

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bessemer Group's VTVT Position: Q2 2026 in Review

Bessemer Group held its vTv Therapeutics (VTVT) position steady in Q2 2026 at 112 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #2330.

Bessemer Group first reported a position in VTVT in Q4 2025 and has held it in 3 quarters since. 45 funds tracked by Wall St. Rank hold VTVT as of Q2 2026.

Bessemer Group held 112 shares of vTv Therapeutics worth $4K as of Q2 2026.
Bessemer Group left its vTv Therapeutics share count unchanged in Q2 2026.
vTv Therapeutics made up ﹤0.01% of Bessemer Group's portfolio in Q2 2026, its #2330 holding.
Bessemer Group first reported a position in vTv Therapeutics in Q4 2025 and has held it in 3 quarters since.
45 funds tracked by Wall St. Rank held vTv Therapeutics as of Q2 2026.

Based on Bessemer Group's 13F filing for Q2 2026, filed 12 Aug 2026.